Candel Therapeutics (CADL)
(Delayed Data from NSDQ)
$6.70 USD
+0.19 (2.92%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $6.72 +0.02 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Candel Therapeutics, Inc. [CADL]
Reports for Purchase
Showing records 1 - 6 ( 6 total )
Company: Candel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results: Significant CAN-2409 and CAN-3110 Readouts; Reiterate Buy Rating and $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Candel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial Phase 2 Data Suggests CAN-2409 Prolongs Survival in Advanced NSCLC Patients; Reiterate Buy Rating and $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Candel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Progress Positions CAN-2409 For Important Near-Term Catalysts; Reiterate Buy Rating and $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Candel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CAN-2409 Making Clinical and Regulatory Progress in 2023; Reiterate Buy and $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Candel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Promising Data Readouts for CAN-2409 in NSCLC and CAN-3110 in HGG; Reiterate Buy and $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Candel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Teaching the Immune System How to Fight Cancer; Initiate at Buy and $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
|